Psycho-pharmaceuticals
AssigneeUniversity College Dublin, National University of Ireland, Dublin
InventorCIARAN REGAN
Life of this patent
Estimating the term…
Abstract
The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) (Captodiamine).
Claims28
A compound comprising a growth factor modulating selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of:
- (a) symptoms of anxiety and/or depression associated with an “affective” disorder;
- and/or (b) symptoms associated with a cognitive impairment disorder in a subject in need of same.
The compound according to any one of the preceding claims wherein the “affective disorder” comprises symptoms of anxiety and/or depression.
The compound according to any one of the preceding claims which has the structure of Formula I below;
- wherein
- X is an ethylene, propylene, butylene or pentylene group;
- R is C1-9 alkyl, preferably C1-5 alkyl;
- R′ is C1-9 alkyl, alkenyl or alkynyl;
- Y is hydrogen, halide such as chloro, fluoro, iodo or bromo, hydroxyC1-4alkyl, amino, C1-4alkylamino, acetylamino or thio;
- and
- Z is hydrogen, halide such as chloro, fluoro, iodo or bromo, hydroxyC1-4alkyl, amino, C1-4alkylamino, acetylamino or thio, or a pharmaceutically acceptable salt thereof.
A diphenhydramine derivative or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of symptoms of anxiety and/or depression associated with an “affective” disorder;
- and/or (b) symptoms associated with a cognitive impairment disorder;
- in a subject in need of same.
A diphenhydramine derivative or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of symptoms of depression associated with an “affective-related” disorder in a subject in need of same.
A diphenhydramine derivative or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of symptoms of anxiety and depression associated with an “affective-related” disorder in a subject in need of same.
A diphenhydramine derivative or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of symptoms associated with a cognitive impairment disorder;
- in a subject in need of same.
A pharmaceutical composition comprising Captodiamine and an agomelatin (Valdoxan).
A process for identifying a compound capable of modulating the expression levels and/or functional activity of a Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand comprising assaying for the ability of the compound to modulate the activity of GDNF.
A compound that modulates the expression levels and/or functional activity of a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand by modulating the expression levels and/or functional activity of GDNF for use in the treatment of symptoms of anxiety and/or depression associated with an “affective” disorder;
- and/or (b) symptoms associated with a cognitive impairment disorder.
A compound comprising a growth factor modulating selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand or a pharmaceutically acceptable salt thereof or a mixture thereof for use in the treatment of (a) symptoms of anxiety and/or depression and/or cognitive impairment associated with a derangement of GDNF signaling in the brain pre-frontal cortex of a subject wherein the treatment comprise administering an effective amount of a GDNF modulating selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand or a pharmaceutically acceptable salt thereof or a mixture thereof to decrease GDNF expression levels in the pre-frontal cortex of the subject's brain.
Dependencies are inferred from the claim text.